On Track for Phase II: Peptomyc Opens €25 Million Round

Peptomyc has focused its project on the development of a new generation of cell-penetrating peptides (CPP) targeting the Myc oncoprotein, with the aim of treating different types of cancer. The company's first candidate has been named OMO103....

On Track for Phase II: Peptomyc Opens €25 Million Round
Peptomyc has focused its project on the development of a new generation of cell-penetrating peptides (CPP) targeting the Myc oncoprotein, with the aim of treating different types of cancer. The company's first candidate has been named OMO103. Peptomyc's horizon is to reach agreements with pharmaceutical companies until the trial is completed in 2024.